Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (81-90 of 190) with videos related to

Pageof 19
Sort By:
Biometrics|August 14, 2009
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trialsNadine Houede, Peter F Thall, Hoang Nguyen, et al.
Clinical Trials (London, England)|June 14, 2023
BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trialsLiyun Jiang, Peter F Thall, Fangrong Yan, et al.
Biometrics|November 7, 2003
Dose-finding with two agents in Phase I oncology trialsPeter F Thall, Randall E Millikan, Peter Mueller, et al.
Clinical Trials (London, England)|April 26, 2007
Simultaneously optimizing dose and schedule of a new cytotoxic agentThomas M Braun, Peter F Thall, Hoang Nguyen, et al.
Journal of Statistical Planning and Inference|January 10, 2012
A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and ToxicityPeter F Thall, Hoang Q Nguyen, Xuemei Wang, et al.
Statistical Methods in Medical Research|September 6, 2017
Bayesian treatment comparison using parametric mixture priors computed from elicited histogramsPeter F Thall, Moreno Ursino, Véronique Baudouin, et al.
Journal of the American Statistical Association|September 8, 2012
Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate CancerLu Wang, Andrea Rotnitzky, Xihong Lin, et al.
Statistics in Medicine|May 19, 2011
Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapiesPeter F Thall, Diane D Liu, Su G Berrak, et al.
Statistics in Medicine|October 24, 2007
Accounting for patient heterogeneity in phase II clinical trialsJ Kyle Wathen, Peter F Thall, John D Cook, et al.
Journal of the American Statistical Association|February 4, 2014
Rejoinder to comments on Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate CancerLu Wang, Andrea Rotnitzky, Xihong Lin, et al.
Pageof 19

Showing results (81-90 of 190) with videos related to

Sort By:
Pageof 19
Biometrics|August 14, 2009
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trialsNadine Houede, Peter F Thall, Hoang Nguyen, et al.
Clinical Trials (London, England)|June 14, 2023
BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trialsLiyun Jiang, Peter F Thall, Fangrong Yan, et al.
Biometrics|November 7, 2003
Dose-finding with two agents in Phase I oncology trialsPeter F Thall, Randall E Millikan, Peter Mueller, et al.
Clinical Trials (London, England)|April 26, 2007
Simultaneously optimizing dose and schedule of a new cytotoxic agentThomas M Braun, Peter F Thall, Hoang Nguyen, et al.
Journal of Statistical Planning and Inference|January 10, 2012
A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and ToxicityPeter F Thall, Hoang Q Nguyen, Xuemei Wang, et al.
Statistical Methods in Medical Research|September 6, 2017
Bayesian treatment comparison using parametric mixture priors computed from elicited histogramsPeter F Thall, Moreno Ursino, Véronique Baudouin, et al.
Journal of the American Statistical Association|September 8, 2012
Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate CancerLu Wang, Andrea Rotnitzky, Xihong Lin, et al.
Statistics in Medicine|May 19, 2011
Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapiesPeter F Thall, Diane D Liu, Su G Berrak, et al.
Statistics in Medicine|October 24, 2007
Accounting for patient heterogeneity in phase II clinical trialsJ Kyle Wathen, Peter F Thall, John D Cook, et al.
Journal of the American Statistical Association|February 4, 2014
Rejoinder to comments on Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate CancerLu Wang, Andrea Rotnitzky, Xihong Lin, et al.
Pageof 19